• 1
    Thase ME, Corya SA, Osuntokun O et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J. Clin. Psychiatry 2007; 68: 224236.
  • 2
    Li XM, Perry KW, Wong DT, Bymaster FP. Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum. Psychopharmacology (Berl.) 1998; 136: 153161.
  • 3
    Berman KF, Weinberger DR. Chapter 26: the prefrontal cortex in schizophrenia and other neuropsychiatric diseases: in vivo physiological correlates of cognitive deficits. Prog. Brain Res. 1990; 85: 521536; discussion 536–537.
  • 4
    Zahrt J, Taylor JR, Mathew RG, Arnsten AF. Supranormal stimulation of D1 dopamine receptors in the rodent prefrontal cortex impairs spatial working memory performance. J. Neurosci. 1997; 17: 85288535.
  • 5
    Maes M, Meltzer H. The serotonin hypothesis of major depression. In : BloomF, KupferD (eds). Psychopharmacology: The Fourth Generation of Progress. Raven Press, New York, 1995; 933944.
  • 6
    Schatzberg A, Schildkraut J. Recent studies on norepinephrine systems in mood disorders. In : BloomF, KupferD (eds). Psychopharmacology: The Fourth Generation of Progress. Raven Press, New York, 1995; 911920.
  • 7
    Willner P. Dopaminergic mechanism in depression and mania. In : BloomF, KupferD (eds). Psychopharmacology: The Fourth Generation of Progress. Raven Press, New York, 1995; 921931.
  • 8
    Robbins TW, Roberts AC. Differential regulation of fronto-executive function by the monoamines and acetylcholine. Cereb. Cortex 2007; 17 (Suppl. 1): i151i160.
  • 9
    Papakostas GI. Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder. J. Clin. Psychiatry 2009; 70 (Suppl. 6): 1625.
  • 10
    Kato T, Hirose A, Ohno Y, Shimizu H, Tanaka H, Nakamura M. Binding profile of SM-9018, a novel antipsychotic candidate. Jpn. J. Pharmacol. 1990; 54: 478481.
  • 11
    Maruoka Y, Ohno Y, Kato T, Hirose A, Tatsuno T, Nakamura M. Effects of SM-9018, a potential atypical neuroleptic, on the central monoaminergic system in rats. Jpn. J. Pharmacol. 1993; 62: 419422.
  • 12
    Ichikawa J, Meltzer HY. Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs. Eur. Arch. Psychiatry Clin. Neurosci. 1999; 249 (Suppl. 4): 9098.
  • 13
    Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003; 27: 11591172.
  • 14
    Arborelius L, Nomikos GG, Hacksell U, Svensson TH. (R)-8-OH-DPAT preferentially increases dopamine release in rat medial prefrontal cortex. Acta Physiol. Scand. 1993; 148: 465466.
  • 15
    Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O'Laughlin IA, Meltzer HY. 5-HT2A and D2 receptor blockade increases cortical DA release via 5-HT1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J. Neurochem. 2001; 76: 15211531.
  • 16
    Blier P, Ward NM. Is there a role for 5-HT1A agonists in the treatment of depression? Biol. Psychiatry 2003; 53: 193203.
  • 17
    Millan MJ, Gobert A, Rivet J-M et al. Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of α2-adrenergic and serotonin2C receptors: a comparison with citalopram. Eur. J. Neurosci. 2000; 12: 10791095.
  • 18
    Millan MJ, Lejeune F, Gobert A. Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents. J. Psychopharmacol. 2000; 14: 114138.
  • 19
    Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. Academic Press, Sydney, 1986.
  • 20
    Schotte A, Bonaventure P, Janssen PF, Leysen JE. In vitro receptor binding and in vivo receptor occupancy in rat and guinea pig brain: risperidone compared with antipsychotics hitherto used. Jpn. J. Pharmacol. 1995; 69: 399412.
  • 21
    Richelson E. Pharmacokinetic interactions of antidepressants. J. Clin. Psychiatry 1998; 59 (Suppl. 10): 2226.
  • 22
    Urichuk L, Prior TI, Dursun S, Baker G. Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr. Drug Metab. 2008; 9: 410418.
  • 23
    Caccia S. New antipsychotic agents for schizophrenia: pharmacokinetics and metabolism update. Curr. Opin. Investig. Drugs 2002; 3: 10731080.
  • 24
    Yoshino T, Nisijima K, Shioda K, Yui K, Katoh S. Perospirone, a novel atypical antipsychotic drug, potentiates fluoxetine-induced increases in dopamine levels via multireceptor actions in the rat medial prefrontal cortex. Neurosci. Lett. 2004; 364: 1621.
  • 25
    Devoto P, Flore G, Pira L, Longu G, Gessa GL. Mirtazapine-induced corelease of dopamine and noradrenaline from noradrenergic neurons in the medial prefrontal and occipital cortex. Eur. J. Pharmacol. 2004; 487: 105111.
  • 26
    Carboni E, Tanda GL, Frau R, Di Chiara G. Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals. J. Neurochem. 1990; 55: 10671070.
  • 27
    Yamamoto BK, Novotney S. Regulation of extracellular dopamine by the norepinephrine transporter. J. Neurochem. 1998; 71: 274280.
  • 28
    Gobert A, Rivet JM, Audinot V, Newman-Tancredi A, Cistarelli L, Millan MJ. Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto- and heteroreceptor-mediated control of release. Neuroscience 1998; 84: 413429.
  • 29
    Nakayama K, Sakurai T, Katsu H. Mirtazapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. Brain Res. Bull. 2004; 63: 237241.
  • 30
    Bonaccorso S, Meltzer HY, Li Z, Dai J, Alboszta AR, Ichikawa J. SR46349-B, a 5-HT2A/2C receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Neuropsychopharmacology 2002; 27: 430441.
  • 31
    Millan MJ, Dekeyne A, Gobert A. Serotonin (5-HT)2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo. Neuropharmacology 1998; 37: 953955.
  • 32
    Haddjeri N, Blier P, de Montigny C. Long-term antidepressant treatments result in a tonic activation of forebrain 5-HT1A receptors. J. Neurosci. 1998; 18: 1015010156.
  • 33
    de Boer T. The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int. Clin. Psychopharmacol. 1995; 10 (Suppl. 4): 1923.